로딩 중…
지수 로딩 중…
지씨셀
144510· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩15,870-6.54%
2026-06-19
Price Chart
지씨셀-21.24%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 250.75B KRW |
| Revenue | 163.35B KRW |
| Net Income | -228.32B KRW |
| Total Assets | 319.90B KRW |
| Net Assets | 190.38B KRW |
| Employees | 811 |
| Value | |
| P/B | 1.32x |
| P/S | 1.54x |
| FCF Yield | 3.16% |
| Profitability | |
| ROE | -119.93% |
| ROA | -71.37% |
| Op. Margin | -2.29% |
| Revenue Growth | -5.50% |
| Financial Health | |
| Debt Ratio | 59.52% |
| Total Debt | 51.61B KRW |
| FCF | 7.92B KRW |
| Cash | 465.0M KRW |
| Current Ratio | 0.53x |
| Dividend | |
| Div. Growth | -71.42% |
| Performance | |
| 1Y Return | -21.24% |
| 1M Return | -19.73% |
| From 52W High | -44.22% |
| 1Y MDD | -42.87% |
| Trading | |
| Volume | 63,459 shares |
| Foreign Own. | 4.88% |
| Per Share | |
| EPS | -16,327 KRW |
| BPS | 12,178 KRW |
Company Info
Established in 2011 through the acquisition of a cell therapy business, this company expanded its operations by merging with Green Cross Cell in 2021. It encompasses the entire process of research and development, manufacturing, commercialization, and distribution within the cell and gene therapy field, offering cell therapies, specimen testing services, and bio-logistics. The company focuses on developing next-generation cell therapies such as CAR-NK and CAR-T, and is expanding indications to autoimmune diseases in collaboration with US company Artiva.